Akums Announces Impressive Q3 FY26 Results and Regulatory Milestones

Akums Drugs & Pharmaceuticals Ltd., a leading CDMO in India, reported strong Q3 FY26 financial results with 16% revenue growth. Improved capacity utilization boosted EBITDA by 21%. The firm earned EU GMP certification for two facilities and UK MHRA approval, reflecting enhanced global compliance and strategic growth.

Akums Drugs & Pharmaceuticals Ltd., India's foremost CDMO, has announced a robust financial performance for Q3 FY26, with significant revenue growth of 16% and a 21% surge in EBITDA year-on-year. The company capitalized on increasing demand, particularly in its international branded formulation segment, driving sequential growth beyond expectations.

An enhanced operational strategy led to a 12.7% EBITDA margin, underscoring the positive impact of improved capacity utilization and tighter cost controls. Recent certifications from the European Union, including EU GMP for Oral Solids and Liquids plants, as well as UK's MHRA approval for Rivaroxaban tablets, highlight Akums' compliance excellence.

Managing Directors Sandeep and Sanjeev Jain emphasized disciplined growth and operational excellence as core drivers behind the company's expanding footprint in regulated markets. Akums' strategic focus is set on strengthening global partnerships while continuing its evolution as a prominent global manufacturing leader.